An integrated molecular docking study of marine bioactive compound as promising drug candidate against SARS CoV-2 receptor in complex with antibody

The Covid-19 pandemic caused by SARS-CoV-19. Due to insufficiency of targeted medication, enforced scientist to form new antiviral drug. We describe our current understanding of Phycocyanobilin, Vidarabine, Avarol, and Mycalamide A, a marine bioactive molecule that having good binding affinity with covid-19 receptor. We perform molecular docking study by using Schrödinger software (maestro v 10.2) for SARS CoV-2 receptor spike protein complexed with neutralizing antibody CT-P59(PDB ID-7CM4) and SARS CoV-2 receptor in complexed with antibody ION-300(PDB ID-7BNV) with marine bioactive compound collected from Pub-chem. database. According to our findings, these compounds have good receptor binding affinity, with Phycocyanobilin and Vidarabine having the highest binding affinity.